Search Results - "Yearby, Brittany"

Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures by Garcia-Manero, Guillermo, Yang, Hui, Fang, Zhihong, Kantarjian, Hagop M., DiNardo, Courtney D., Jabbour, Elias J., Pemmaraju, Naveen, Daver, Naval, Delumpa, Ricardo, Loiselle, Christopher, Rivera, Silvia, Anderson, Kristin, Yearby, Brittany, Denton, Susan, Smith, Whitney, Tiefenwerth, Kathleen, Iwamura, Hiroyuki, Gipson, Teletha, Rosner, Michele, Myers, Thomas J., Paradiso, Linda J.

“…Inosine 5'- monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme that catalyzes de novo synthesis of the guanine nucleotide and is overexpressed in…”
Get full text

Phase I/II Study of Ruxolitinib for Minimal Residual Disease in Chronic Myeloid Leukemia by Maiti, Abhishek, Kantarjian, Hagop M., Jabbour, Elias J., Poku, Rebecca, Yearby, Brittany A, Breakefield, Stephanie, Ravandi, Farhad, Cortes, Jorge E.

“…Background: In chronic myeloid leukemia (CML), deep molecular responses improve long-term prognosis, and patients (pt) with sustained MR4.5 are candidates for…”
Get full text

A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure by Swaminathan, Mahesh, Borthakur, Gautam, Kadia, Tapan M., Ferrajoli, Alessandra, Alvarado, Yesid, Pemmaraju, Naveen, Bodden, Kristy, Yearby, Brittany, Konopleva, Marina, Khoury, Joseph, Bueso-Ramos, Carlos, Garcia-Manero, Guillermo, DiNardo, Courtney D.

“…Hypomethylating agents (HMA) are the standard of care for treatment of myelodysplastic syndromes (MDS). HMA-failure MDS has extremely poor prognosis. This…”
Get full text